Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single ascending dose phase Ib trial investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB 324 in healthy volunteers

Next Previous
X
Search
Trial Profile

Single ascending dose phase Ib trial investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB 324 in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Apr 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bemcentinib (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Non-small cell lung cancer
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
  • Sponsors BerGenBio

    • Most Recent Events

    • 09 Apr 2014 Status changed from recruiting to completed.
    • 09 Apr 2014 Results were presented at the Annual Meeting of the American Association of Cancer Research (AACR) in April 2014.
    • 05 Feb 2014 Results are expected in 2015 according to a BerGenBio media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top